GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Concord Biotech Ltd

Concord Biotech Q2 FY27 Consolidated Revenue Up 25.1% to Rs. 309.1 Crs

RESULTS ▲ Positive Development LOW RISK
📅 Filed on BSE: 27 Oct 2026, 08:21 PM IST  ·  BSE ID: f3994943-2353-4203-9f7f-b0b4da3c6e56
View Original BSE Filing (PDF)
💡
In Simple Terms
The company increased its sales and profit, launched a new dermatology product line, and fixed a record date for bonus shares.
🤖 AI Summary
  • Concord Biotech's Q2 FY27 consolidated revenue from operations grew 25.1% to Rs. 309.1 Crs, with H1 FY27 revenue at Rs. 566.6 Crs.
  • Q2 FY27 consolidated net profit after tax increased by 10.3% to Rs. 69.6 Crs, while H1 FY27 PAT rose 19.0% to Rs. 127.3 Crs.
  • The company launched a new dermatology division, Inspira, and completed a USFDA inspection at its Unit II formulation facility with one minor observation.
  • Concord Biotech received approvals for Tofacitinib and MMF OS ANDAs and announced a 1:1 bonus share issuance.
  • Q2 FY27 EBITDA margin was 33.8% and PAT margin was 22.5%, both lower than the previous year due to higher input costs and product mix changes.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Consolidated Revenue from Operations Q2 FY27
309.1 Crs
25.1%
Consolidated PAT Q2 FY27
69.6 Crs
10.3%
Consolidated Revenue from Operations H1 FY27
566.6 Crs
25.6%
Consolidated PAT H1 FY27
127.3 Crs
19.0%
Q2 FY27 Gross Profit Margin
76.2%
Q2 FY27 EBITDA Margin
33.8%
Q2 FY27 PAT Margin
22.5%
🏢 How This Affects the Company
📈
Business Impact
The launch of the Inspira dermatology division expands the company's product portfolio and market presence into a new segment. The 25.1% YoY revenue growth in Q2 FY27 indicates continued market penetration and demand for existing products.
💰
Financial Impact
Consolidated revenue from operations increased by Rs. 62.0 Crs in Q2 FY27 compared to Q2 FY26. While net profit increased by Rs. 6.5 Crs, the PAT margin decreased from 25.5% to 22.5% due to higher input costs and product mix shifts.
⚙️
Operational Impact
Successful completion of the USFDA inspection at the Unit II formulation facility ensures continuity of international supplies and reinforces global compliance standards. The approval of Tofacitinib and MMF OS ANDAs expands the range of products for US and other regulated markets.
⚠️
Risk Impact
No new risks were introduced by this filing. The minor procedural observation from the USFDA inspection was noted as unrelated to GMP, mitigating immediate operational risk.
👥 What This Means For Shareholders
✅
Action Required
Shareholders should note the record date fixed for the bonus share issue announced in a previous filing.
👤
Who Is Affected
Existing shareholders will receive bonus shares in the ratio of 1:1, meaning one additional share for every share held. This increases the total number of shares owned by each shareholder.
🔍
Management Signal
The approval of a 1:1 bonus share issue signals management's confidence in the company's sustained profitability and future earnings potential.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Q3 FY27 financial results — assess sustained revenue and profit growth.
Update on Inspira dermatology division market reception and sales.
Progress on commercialization of Tofacitinib and MMF OS ANDAs.
LOW RISK The filing reports strong financial performance and strategic expansions, with no significant new risks identified.
💡 Investor Takeaway
Concord Biotech reported Q2 FY27 consolidated revenue of Rs. 309.1 Crs, a 25.1% increase YoY, with net profit after tax reaching Rs. 69.6 Crs, up 10.3%. H1 FY27 consolidated revenue stood at Rs. 566.6 Crs, a 25.6% increase YoY, with PAT at Rs. 127.3 Crs, up 19.0%.
⚖️ Strengths & Concerns

✅ Positives

  • Q2 FY27 consolidated revenue from operations increased by 25.1% year-on-year to Rs. 309.1 Crs, indicating strong top-line growth.
  • The company successfully completed a USFDA inspection at its Unit II formulation facility with only one minor procedural observation.

⚠️ Concerns

  • Q2 FY27 consolidated Gross Profit Margin decreased by 400 bps YoY to 76.2%, and PAT Margin decreased by 300 bps to 22.5%.
  • EBITDA margin (excluding impact of Injectable Facility & Expenses related to Stellon Biotech) stood at 37.1% for Q2FY27, lower than prior periods.
📅 Company Track Record
Concord Biotech's Q1 FY27 consolidated revenue increased by 26% to Rs. 257.5 Crs, with PAT up 31%. This Q2 FY27 filing continues the trend of strong double-digit revenue and PAT growth.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Concord Biotech's consolidated revenue in Q2 FY27?
Concord Biotech reported consolidated revenue from operations of Rs. 309.1 Crs for the second quarter ended September 30, 2026, marking a 25.1% increase year-on-year.
What was Concord Biotech's net profit after tax for Q2 FY27?
The consolidated net profit after tax for Concord Biotech in Q2 FY27 was Rs. 69.6 Crs, which represents a 10.3% increase compared to Q2 FY26.
How did Concord Biotech's margins perform in Q2 FY27?
Concord Biotech's consolidated Gross Profit Margin for Q2 FY27 was 76.2%, EBITDA Margin was 33.8%, and PAT Margin was 22.5%. Margins were impacted by higher input costs and a change in product mix.
What new division did Concord Biotech launch in Q2 FY27?
Concord Biotech launched a new dermatology division named 'Inspira' during Q2 FY27, expanding its presence into science-led skin solutions.
What is the status of Concord Biotech's USFDA inspection?
Concord Biotech completed a USFDA inspection at its Unit II formulation facility in Valthera, Ahmedabad, with one minor procedural observation noted that was unrelated to GMP.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.